And consider that the merger between Sanofi-Synthelabo and Aventis is not yet three years old.
It was formed in 2004 in a merger between two French companies, Sanofi-Synthelabo and Aventis.
Analysts generally expect Bristol and Sanofi-Synthelabo , which developed Plavix, to triumph, but they've been wrong before.
Her choice, Aventis, closed the contest up 62%, thanks to a takeover bid from French pharmaceutical firm Sanofi-Synthelabo.
Acomplia, from Sanofi-Synthelabo (nyse: SNY - news - people ), could be available in two years.
That point was driven home today by the regulatory approval of Eloxatin, or oxaliplatin, a treatment for colorectal cancer developed by Sanofi-Synthelabo .
Rimonabant is being developed under the trade name Acomplia by French drugmaker Sanofi-Synthelabo (nyse: SNY - news - people ).
The French drugmaker Sanofi-Synthelabo might make a better partner, however.
For example, Bristol-Myers and ImClone are now in trials combining Erbitux with yet another colon cancer chemo drug, oxaliplatin from Sanofi-Synthelabo (nyse: SNY - news - people ).
To benchmark oncologists' desire to use Avastin, some Wall Street analysts are using a chemotherapy, Eloxatin from Sanofi-Synthelabo (nyse: SNY - news - people ), as their benchmark.
Ambien, sold by French drug giant Sanofi-Synthelabo (nyse: SNY - news - people ), is currently the only one of these new sleeping pills approved by the U.S. Food and Drug Administration.
Paris-based Sanofi-Synthelabo (nyse: SNY - news - people ) was sent back to the drawing board and returned with a trial that took a more conservative approach, asking for approval only as a second-line medicine.
Basel, Switzerland-based Novartis (nyse: NVS - news - people ) issued a statement this morning confirming that it has done detailed feasibility studies on a white knight bid for Aventis (nyse: AVE - news - people ), which is the target of a hostile takeover by Sanofi-Synthelabo (nyse: SNY - news - people ).
应用推荐